ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND SAFETY OF BMS-488043, A NOVEL ORAL SMALL-MOLECULE HIV-1 ATTACHMENT INHIBITOR, IN HIV-1-INFECTED SUBJECTS

HANNA, G.J., LALEZARI, J., & HELLINGER, J.A.. (2011). ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND SAFETY OF BMS-488043, A NOVEL ORAL SMALL-MOLECULE HIV-1 ATTACHMENT INHIBITOR, IN HIV-1-INFECTED SUBJECTS. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 55(2), 722-728. SID. https://sid.ir/paper/634596/en

HANNA G.J., LALEZARI J., HELLINGER J.A.. ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND SAFETY OF BMS-488043, A NOVEL ORAL SMALL-MOLECULE HIV-1 ATTACHMENT INHIBITOR, IN HIV-1-INFECTED SUBJECTS. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY[Internet]. 2011;55(2):722-728. Available from: https://sid.ir/paper/634596/en

G.J. HANNA, J. LALEZARI, and J.A. HELLINGER, “ANTIVIRAL ACTIVITY, PHARMACOKINETICS, AND SAFETY OF BMS-488043, A NOVEL ORAL SMALL-MOLECULE HIV-1 ATTACHMENT INHIBITOR, IN HIV-1-INFECTED SUBJECTS,” ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 55, no. 2, pp. 722–728, 2011, [Online]. Available: https://sid.ir/paper/634596/en